Kailera Therapeutics, listed on Nasdaq as KLRA and based in Waltham, Massachusetts, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, with Ron Renaud, president and chief executive officer, scheduled to speak at 10:30 a.m. EDT. A live webcast will be available on t…
Researchers in South Korea say they have made a major advance by turning on genes with an electromagnetic signal, but critics say the claims are implausible and the paper is flawed
Embryo organoids made from stem cells are enabling scientists to recreate early pregnancy in the lab, unlocking treatments for infertility, miscarriage and pre-eclampsia
Chai Discovery appoints ex-Pfizer CSO to board after latest model delivers ‘fully de novo’ antibody design with a 20% hit rate. AI drug development startup Chai Discovery has secured $70 million in a Series A funding round led by Menlo Ventures, bringing its total funding to over $100 million. The O…
Next-generation MS platforms are transforming drug discovery by revealing complex biology earlier, faster, and at unprecedented depth. The post Mass Spectrometry’s Discovery Revolution appeared first on GEN - Genetic Engineering and Biotechnology News.
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Jocasta targets clinical trials of klotho-based therapy in 2026, building on technology licensed from Unity Bio. While the recent demise of Unity Biotechnology came as a blow to the longevity field, its impact on the field will continue to be felt for many years to come, including through the work b…
FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, announced significant advancements in its Bone Marrow Organoid (BMO) platform, which may offer new treatment options for hematopoietic cancers and age-related immune decline. The company reported that pre-IND animal trials …
Cross-licensing agreement brings reformulated rimiducid to cell and gene therapies, with implications for oncology and longevity medicine. The University of Texas MD Anderson Cancer Center and Phoenix SENOLYTIX have announced a global cross-licensing agreement around CaspaCIDe, the preeminent cell t…
ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities appeared first on GEN - Genetic Engineering and Biotechnology News.
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
As FDA support for NAMs accelerates, Corning is helping researchers standardize, scale, and automate organoid science. The post Corning Advances the Organoid Revolution appeared first on GEN - Genetic Engineering and Biotechnology News.
Phoenix and Eos SENOLYTIX to present dual approaches to tackling aging at the 2nd Senotherapeutics Summit. The second Senotherapeutics Summit in Rome will be a significant draw for anyone interested in the next frontier of longevity biotechnology. Senescent cells – damaged, non-dividing cells that a…
Alterity Therapeutics has disclosed results from its Phase 2 ATH434-201 clinical trial in patients with Multiple System Atrophy (MSA), according to the company. The randomized, double-blind, placebo-controlled study evaluated two doses of ATH434 (50 mg and 75 mg twice daily) over 12 months in 77 adu…
HCW Biologics, a clinical-stage biopharmaceutical company, has designated one of its proprietary TRBC-pembrolizumab-based immune checkpoint inhibitors as its franchise immunotherapeutic to be advanced into internal clinical development for treating solid tumours. The company said that this lead cand…
Rona Therapeutics has filed an Investigational New Drug (IND) application with the Australian Human Research Ethics Committee for RN3161, a GalNAc-conjugated small interfering RNA (siRNA) designed to target the gene INHBE as a therapy for adults with overweight and obesity. According to the company,…
Bio Protocol’s first longevity-focused initiative, Aubrai, raised more than $900,000 in research funding within weeks. Decentralized science company Bio Protocol has raised $6.9 million to expand its AI-native DeSci platform designed to accelerate biotech funding and drug discovery. The round, coinc…
Using duckweed as an alternative to mammalian expression systems can ease manufacturers’ transition from blockbuster to biosimilar. The post Turning the Patent Cliff into a Bioplant Opportunity appeared first on GEN - Genetic Engineering and Biotechnology News.
From lab-grown mini livers to engineered bile ducts, regenerative medicine is beginning to change how it approaches aging and organ failure. Liver disease has occupied an uncomfortable place in medicine. It is widespread, often silent for decades and, once advanced, notoriously difficult to reverse.…
